Photo from Anas Younes/LinkedIn
Jul 19, 2024, 14:44
“What’s Next for Immunotherapies?” by Anas Younes
“My interview with Mark Cobbold, Senior Vice President of Discovery, Immuno-Oncology, and Head of Oncology Cell Therapy, Oncology R&D, AstraZeneca.” .
Source: LinkedIn
Anas Younes is the Senior Vice President and Global Head of Hematology (Early and Late Stage) Oncology R&D at AstraZeneca. Prior to working for AstraZeneca, he was the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, and a Professor of Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX. His interests include HL, NHL, developing novel targeted therapies for lymphoma, identification of biomarkers for treatment, and participation in clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 18:02
Dec 22, 2024, 17:54
Dec 22, 2024, 17:51
Dec 22, 2024, 17:47
Dec 22, 2024, 17:44
Dec 22, 2024, 17:39
Dec 22, 2024, 17:36
Dec 22, 2024, 17:32
Dec 22, 2024, 17:18